Minerva Begins Phase 3 Trial of MIN-101 for Schizophrenia

Minerva Neurosciences has initiated a phase 3 clinical trial of their investigational compound MIN-101 for the treatment of negative symptoms of schizophrenia in adults.

MIN-101 is a cyclic amide derivative that has primary affinities for the sigma-2 receptor and 5-HT2A serotonin receptor.

The 12-week randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of 32 mg and 64 mg doses of MIN-101 in adult patients with schizophrenia. After 12 weeks, all patients will be given the option to receive MIN-101 a 40-week, open-label extension period. Researchers hope to recruit 500 patients for the trial, which will be conducted at 60 clinical sites. ■